OBJECTIVE: To present estimations obtained from a population-level survey conducted in Mexico of prevalence rates of mono-, poly- and multidrug-resistant strains among newly diagnosed cases of pulmonary tuberculosis (TB), as well as the main factors associated with multidrug resistance (combined resistance to isoniazid and rifampicin). DESIGN: Study data came from the National Survey on TB Drug Resistance (ENTB-2008), a nationally representative survey conducted during 2008-2009 in nine states with a stratified cluster sampling design. Samples were obtained for all newly diagnosed cases of pulmonary TB in selected sites. Drug susceptibility testing (DST) was performed for anti-tuberculosis drugs. RESULTS: DST results were obtained for 75% of the cases. Of these, 82.2% (95%CI 79.5-84.7) were susceptible to all drugs. The prevalence of multidrug-resistant TB (MDR-TB) was estimated at 2.8% (95%CI 1.9-4.0). MDR-TB was associated with previous treatment (OR 3.3, 95%CI 1.1-9.4). CONCLUSIONS: The prevalence of drug resistance is relatively low in Mexico. ENTB-2008 can be used as a baseline for future follow-up of drug resistance.
OBJECTIVE: To present estimations obtained from a population-level survey conducted in Mexico of prevalence rates of mono-, poly- and multidrug-resistant strains among newly diagnosed cases of pulmonary tuberculosis (TB), as well as the main factors associated with multidrug resistance (combined resistance to isoniazid and rifampicin). DESIGN: Study data came from the National Survey on TB Drug Resistance (ENTB-2008), a nationally representative survey conducted during 2008-2009 in nine states with a stratified cluster sampling design. Samples were obtained for all newly diagnosed cases of pulmonary TB in selected sites. Drug susceptibility testing (DST) was performed for anti-tuberculosis drugs. RESULTS: DST results were obtained for 75% of the cases. Of these, 82.2% (95%CI 79.5-84.7) were susceptible to all drugs. The prevalence of multidrug-resistant TB (MDR-TB) was estimated at 2.8% (95%CI 1.9-4.0). MDR-TB was associated with previous treatment (OR 3.3, 95%CI 1.1-9.4). CONCLUSIONS: The prevalence of drug resistance is relatively low in Mexico. ENTB-2008 can be used as a baseline for future follow-up of drug resistance.
Authors: Courtney M Yuen; Helen E Jenkins; Carly A Rodriguez; Salmaan Keshavjee; Mercedes C Becerra Journal: Pediatrics Date: 2015-06-01 Impact factor: 7.124
Authors: Ietza Bojorquez; Richard F W Barnes; Jennifer Flood; Hugo López-Gatell; Richard S Garfein; Claudia E Bäcker; Celia Alpuche; Joseph M Vinetz; Antonino Catanzaro; Midori Kato-Maeda; Timothy C Rodwell Journal: Am J Public Health Date: 2013-05-16 Impact factor: 9.308
Authors: Carla DeSisto; Kelly Broussard; Miguel Escobedo; Denise Borntrager; Francisco Alvarado-Ramy; Stephen Waterman Journal: Am J Trop Med Hyg Date: 2015-08-24 Impact factor: 2.345
Authors: Miriam Bobadilla-del Valle; Pedro Torres-González; Miguel Enrique Cervera-Hernández; Areli Martínez-Gamboa; Brenda Crabtree-Ramirez; Bárbara Chávez-Mazari; Narciso Ortiz-Conchi; Luis Rodríguez-Cruz; Axel Cervantes-Sánchez; Tomasa Gudiño-Enríquez; Carmen Cinta-Severo; José Sifuentes-Osornio; Alfredo Ponce de León Journal: PLoS Negl Trop Dis Date: 2015-09-30